Literature DB >> 16333084

Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda.

François Chappuis1, Yolanda Mueller, Alexandre Nguimfack, John Bosco Rwakimari, Sophie Couffignal, Marleen Boelaert, Philippe Cavailler, Louis Loutan, Patrice Piola.   

Abstract

The development of an accurate, practical, and affordable diagnostic test is essential to improve the management of visceral leishmaniasis (VL) in remote health centers. We evaluated the Formol Gel test (FGT) and two rK39 antigen-based dipsticks, the DUAL-IT L/M, and the Kalazar Detect for VL diagnosis in Amudat Hospital in Uganda. The DUAL-IT L/M was also evaluated for the diagnosis of malaria. All patients clinically suspect of VL were prospectively included in the study between October 2003 and March 2004. The gold standard used to define a VL case was a positive spleen aspirate or a direct agglutination test titer of >1:12,800 with an appropriate clinical response to antileishmanial therapy. A total of 131 VL and 112 non-VL patients were included in the analysis. The DUAL IT L/M was found to be more sensitive than the Kalazar Detect: 97% (95% confidence interval [95%CI] = 92 to 99%) versus 82% (95%CI = 74 to 87%). The Kalazar Detect and the DUAL IT L/M were highly specific (99% [95%CI = 95 to 100%] and 97% [95%CI = 92 to 99%], respectively). The FGT lacked both sensitivity (66% [95%CI = 57 to 73%]) and specificity (90% [95%CI = 83 to 94%]). The sensitivity of the DUAL IT L/M for malaria was only 57% (95%CI = 37 to 76%). The two rK39 dipsticks can be used for diagnostic confirmation of VL in this region. The DUAL-IT L/M without its malaria diagnostic component (DiaMed-IT LEISH) will be adopted as first-line test for VL in Uganda.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16333084      PMCID: PMC1317204          DOI: 10.1128/JCM.43.12.5973-5977.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Cost-effectiveness of competing diagnostic-therapeutic strategies for visceral leishmaniasis.

Authors:  M Boelaert; L Lynen; P Desjeux; P Van der Stuyft
Journal:  Bull World Health Organ       Date:  1999       Impact factor: 9.408

2.  Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan.

Authors:  E E Zijlstra; Y Nur; P Desjeux; E A Khalil; A M El-Hassan; J Groen
Journal:  Trop Med Int Health       Date:  2001-02       Impact factor: 2.622

3.  Latent class analysis permits unbiased estimates of the validity of DAT for the diagnosis of visceral leishmaniasis.

Authors:  M Boelaert; S el Safi; E Goetghebeur; S Gomes-Pereira; D Le Ray; P Van der Stuyft
Journal:  Trop Med Int Health       Date:  1999-05       Impact factor: 2.622

4.  Multi-centre evaluation of repeatability and reproducibility of the direct agglutination test for visceral leishmaniasis.

Authors:  M Boelaert; S El Safi; H Mousa; J Githure; P Mbati; V l Gurubacharya; J Shrestha; D Jacquet; A De Muynck; D Le Ray; P Van der Stuyft
Journal:  Trop Med Int Health       Date:  1999-01       Impact factor: 2.622

5.  Evaluation of the direct agglutination test and the rK39 dipstick test for the sero-diagnosis of visceral leishmaniasis.

Authors:  Henk D F H Schallig; Marilene Canto-Cavalheiro; Eduardo S da Silva
Journal:  Mem Inst Oswaldo Cruz       Date:  2002-10       Impact factor: 2.743

6.  Value of a dipstick based on recombinant RK39 antigen for differential diagnosis of American visceral leishmaniasis from other sympatric endemic diseases in Venezuela.

Authors:  O Delgado; M D Feliciangeli; V Coraspe; S Silva; A Perez; J Arias
Journal:  Parasite       Date:  2001-12       Impact factor: 3.000

7.  Rapid accurate field diagnosis of Indian visceral leishmaniasis.

Authors:  S Sundar; S G Reed; V P Singh; P C Kumar; H W Murray
Journal:  Lancet       Date:  1998-02-21       Impact factor: 79.321

Review 8.  Leishmaniasis. Public health aspects and control.

Authors:  P Desjeux
Journal:  Clin Dermatol       Date:  1996 Sep-Oct       Impact factor: 3.541

9.  Comparison of the OptiMAL rapid test and microscopy for detection of malaria in pregnant women in Nigeria.

Authors:  T A VanderJagt; E I Ikeh; I O A Ujah; J Belmonte; R H Glew; D J VanderJagt
Journal:  Trop Med Int Health       Date:  2005-01       Impact factor: 2.622

10.  Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis.

Authors:  Koert Ritmeijer; Yoseph Melaku; Marius Mueller; Sammy Kipngetich; Caroline O'keeffe; Robert N Davidson
Journal:  Am J Trop Med Hyg       Date:  2006-01       Impact factor: 2.345

View more
  30 in total

Review 1.  Diagnosis of visceral leishmaniasis: developments over the last decade.

Authors:  Gurumurthy Srividya; Arpita Kulshrestha; Ruchi Singh; Poonam Salotra
Journal:  Parasitol Res       Date:  2011-11-09       Impact factor: 2.289

2.  Evaluation of two rK39 dipstick tests, direct agglutination test, and indirect fluorescent antibody test for diagnosis of visceral leishmaniasis in a new epidemic site in highland Ethiopia.

Authors:  Carmen Cañavate; Merce Herrero; Javier Nieto; Israel Cruz; Carmen Chicharro; Pilar Aparicio; Abate Mulugeta; Daniel Argaw; Anna J Blackstock; Jorge Alvar; Caryn Bern
Journal:  Am J Trop Med Hyg       Date:  2011-01       Impact factor: 2.345

Review 3.  A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis.

Authors:  François Chappuis; Suman Rijal; Alonso Soto; Joris Menten; Marleen Boelaert
Journal:  BMJ       Date:  2006-08-01

4.  Performance of two immunochromatographic tests for diagnosis of visceral leishmaniasis in patients coinfected with HIV.

Authors:  Mauro Roberto Biá da Silva; Natália Alberto Alves Brandão; Marco Colovati; Margella Marconcine Pinheiro de Sousa; Larissa Coelho de Lima; Miriam Leandro Dorta; Fátima Ribeiro-Dias; Dorcas Lamounier Costa; Carlos Henrique Nery Costa; Milton Adriano Pelli de Oliveira
Journal:  Parasitol Res       Date:  2017-12-21       Impact factor: 2.289

5.  Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis.

Authors:  Sowmya Pattabhi; Jacqueline Whittle; Raodoh Mohamath; Sayda El-Safi; Garner G Moulton; Jeffrey A Guderian; Danny Colombara; Asem O Abdoon; Maowia M Mukhtar; Dinesh Mondal; Javan Esfandiari; Shailendra Kumar; Peter Chun; Steven G Reed; Ajay Bhatia
Journal:  PLoS Negl Trop Dis       Date:  2010-09-14

6.  Diagnostic accuracy of the Leishmania OligoC-TesT and NASBA-Oligochromatography for diagnosis of leishmaniasis in Sudan.

Authors:  Alfarazdeg A Saad; Nuha G Ahmed; Osman S Osman; Ahmed Almustafa Al-Basheer; Awad Hamad; Stijn Deborggraeve; Philippe Büscher; Gerard J Schoone; Henk D Schallig; Thierry Laurent; Ahmed Haleem; Omran F Osman; Ahmed Mohamedain Eltom; Mustafa I Elbashir; Sayda El-Safi
Journal:  PLoS Negl Trop Dis       Date:  2010-08-03

7.  A Rare Presentation of Leishmaniasis.

Authors:  Ritesh Prajapati; Ashish Kumar; Praveen Sharma; Vikas Singla; Naresh Bansal; Shashi Dhawan; Anil Arora
Journal:  J Clin Exp Hepatol       Date:  2016-01-14

8.  Specificity of the rapid rK39 antigen-based immunochromatographic test Kalazar Detect(r) in patients with cutaneous leishmaniasis in Brazil.

Authors:  Félix Javier León Molinet; Julia Sonia Ampuero; Rodrigo Diniz Costa; Elza Ferreira Noronha; Gustavo Adolfo Sierra Romero
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-05       Impact factor: 2.743

Review 9.  Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease.

Authors:  Marleen Boelaert; Kristien Verdonck; Joris Menten; Temmy Sunyoto; Johan van Griensven; Francois Chappuis; Suman Rijal
Journal:  Cochrane Database Syst Rev       Date:  2014-06-20

10.  Kala-azar control, Uganda.

Authors:  Jan H Kolaczinski; Dagemlidet Tesfaye Worku; François Chappuis; Richard Reithinger; Narcis Kabatereine; Ambrose Onapa; Simon Brooker
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.